| | Term | Multiple imputation | Case exclusion |
| | Isoniazid resistance | 2.07 (1.30, 3.29) | 1.53 (0.83, 2.83) | | Male gender | 1.20 (0.88, 1.63) | 1.16 (0.81, 1.66) | | Age categories | | | | Age ≤ 1 | 0.076 (0.008, 0.69) |
+ | | 1 < Age ≤ 4 | 0.23 (0.067, 0.82) | 0.61 (0.13, 2.79) | | 4 < Age ≤ 14 | 0.38 (0.102, 1.41) |
+ | | 14 < Age ≤ 24 | 1.22 (0.64, 2.34) | 1.44 (0.71, 2.93) | | 24 < Age ≤ 34 | Reference | | | 34 < Age ≤ 44 | 1.30 (0.87, 1.92) | 1.11 (0.69, 1.78) | | 44 < Age ≤ 54 | 1.97 (1.23, 3.15) | 1.87 (1.12, 3.13) | | 54 < Age ≤ 64 | 1.83 (1.09, 3.09) | 1.13 (0.57, 2.23) | | 64 < Age ≤ 74 | 4.36 (2.48, 7.67) | 5.85 (2.80, 12.19) | | Age > 74 | 6.90 (3.85, 12.38) | 2.99 (1.25, 7.12) | | Race categories | | | | White | Reference | | | Black | 1.44 (1.01, 2.06) | 1.10 (0.69, 1.76) | | Hispanic | 1.21 (0.74, 1.99) | 1.19 (0.71, 1.98) | | Asian* | 0.64 (0.30, 1.35) | 0.62 (0.30, 1.28) | | American Indian | 9.07 (2.65, 31.02) | 28.5 (3.12, 260.2) | | Other** | 0.85 (0.20, 3.52) | 0.81 (0.15, 4.43) | | HIV positive | 3.57 (1.87, 6.82) | 4.58 (3.13, 6.71) |
|
|
